POINT Biopharma to Present on its Pan-Cancer FAP-Alpha Targeted Program at the AACR Annual Meeting
April 11, 2022 16:30 ET
|
POINT Biopharma
POINT’s PNT6555 is a potent and specific inhibitor of Fibroblast Activation Protein (FAP), a phase 1 therapeutic trial using 68Ga-PNT6555 for imaging and 177Lu-PNT6555 for therapy is planned for...
Global Demand of Radiopharmaceutical Market Size & Share Value Will Cross USD 11.8 Billion by 2028, with a Stellar CAGR of 10.5% Growth | Radiopharmaceutical Industry Trends & Forecast Report by Facts & Factors
April 11, 2022 11:00 ET
|
Facts & Factors
LONDON, UK, April 11, 2022 (GLOBE NEWSWIRE) -- Facts and Factors has published a new research report titled “Radiopharmaceutical Market By Type (Therapeutic and Diagnostic), By Application...
Global Radiopharmaceuticals Market to 2030 - Featuring Cardinal Health, Curium Pharma and Siemens Healthineers Among Others
April 06, 2022 06:23 ET
|
Research and Markets
Dublin, April 06, 2022 (GLOBE NEWSWIRE) -- The "Radiopharmaceuticals Global Market Opportunities And Strategies To 2030, By Type, Application, End-User" report has been added to...
POINT Biopharma Reports Fiscal 2021 Financial Results and Provides Business Update
March 25, 2022 08:30 ET
|
POINT Biopharma
Reported 27-patient dosimetry data from the lead-in cohort of the SPLASH trial Randomization phase of SPLASH trial ongoing, top line data expected mid-2023 Phase 1 therapeutic trial for PNT6555, the...
POINT Biopharma Confirms No Delays to SPLASH Trial Due to Recent Global Lutetium Supply Interruption
March 22, 2022 08:30 ET
|
POINT Biopharma
INDIANAPOLIS, March 22, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to...
Global Radiopharmaceuticals Market Analysis Report 2021: Market to Reach $8.9 Billion by 2026 - COVID-19 Presents Generational Opportunity
January 27, 2022 04:43 ET
|
Research and Markets
Dublin, Jan. 27, 2022 (GLOBE NEWSWIRE) -- The "Radiopharmaceuticals - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering. Global...
Global Nuclear Medicine Markets, Analysis, Forecast & Opportunities, 2016-2020 & 2021-2026
December 31, 2021 09:33 ET
|
Research and Markets
Dublin, Dec. 31, 2021 (GLOBE NEWSWIRE) -- The "Global Nuclear Medicine Market, By Type, By Diagnostic Nuclear Medicine, By Therapeutic Nuclear Medicine, By Application, By Diagnostic Applications,...
Curium Initiates ECLIPSE, a Phase 3 Clinical Trial For Its Investigational Lu 177 PSMA I&T
October 27, 2021 02:15 ET
|
Curium
St. Louis, MO, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Curium announced today that the Company has received a Study May Proceed letter from the U.S. Food and Drug Administration (FDA) to begin its Phase 3...
Outlook on the Radiotherapy, Radiopharmaceuticals and Nuclear Medicine Global Market to 2026 - Featuring Accuray, Bayer Pharma and Nordion Among Others
October 26, 2021 07:13 ET
|
Research and Markets
Dublin, Oct. 26, 2021 (GLOBE NEWSWIRE) -- The "Radiotherapy, Radiopharmaceuticals and Nuclear Medicine: Global Markets" report has been added to ResearchAndMarkets.com's offering. This report...
Global Nuclear Medicine/Radiopharmaceuticals Market (2021 to 2026) - Use of Radiopharmaceuticals in Neurological Applications Presents Opportunities
September 21, 2021 06:23 ET
|
Research and Markets
Dublin, Sept. 21, 2021 (GLOBE NEWSWIRE) -- The "Global Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET - F-18), Therapeutic (Beta Emitters - I-131, Alpha...